Friday, July 10, 2026

Drug profile · INN

daclatasvir

daclatasvir (DAKLINZA) is an FDA-listed pharmaceutical active ingredient.

EMA: unknown Antiinfectives for systemic use (J05) J05AP07
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — daclatasvir
Class
Antiinfectives for systemic use (J05)
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

daclatasvir (DAKLINZA) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN daclatasvir
Brand DAKLINZA
Therapeutic class Antiinfectives for systemic use (J05)
ATC code J05AP07

Approval history

Authority Status Date
EMA unknown

Pipeline programs

  1. Daclatasvir Phase 3 · Bristol Myers Squibb · Hepatitis C Virus Infection
  2. daclatasvir Phase 3 · Chinese Academy of · Hepatitis C

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is daclatasvir?

daclatasvir (DAKLINZA) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for daclatasvir?

DAKLINZA is a marketed brand name for daclatasvir. Check FDA Drugs@FDA for the current US label holder and prescribing information.